Four years ago, old high-school buddies Nicholas Quinn and Jesse Moors were taking in the sunshine at a café on Melbourne’s Southbank, when they decided to take their mutual interest in stock market investment to the next level. Quinn, a former PwC global tax specialist, and Moors, formerly a business development manager at CPA Australia,…
OK, so you want to own a big global diversified bulk miner, to take advantage of the impending commodities boom – let’s take a look at the contenders, BHP and Rio Tinto. Here’s the tale of the tape. BHP (BHP, $36.35)Market capitalisation: $183.7 billionOne-year total return: +6.9%Three-year total return: +17.9% a yearFive-year total return: +14.2%…
One of the great investment success stories of the last 25 years has been the exchange-traded fund (ETF), which got under way in the early 1990s as a vehicle offering access, in one listed stock, to the entire stock market through tracking an index. Gone were the worries of paying “active” management fees and failing…
Here’s the fourth instalment of our series on the fascinating ASX cohort of medical device developers. ImpediMed (IPD, 8.1 cents)Market capitalisation: $83.8 millionThree-year total return: -52.7% a yearAnalysts’ consensus target price: 14 cents (Thomson Reuters) You would not know it from the share price performance over the last few years, but Brisbane-based ImpediMed has put…
With the deleveraging plans out in the marketplace, analysts think there is more value in the European/North American angle when it comes to the Westfield story, with consensus target prices for Unibail-Rodamco-Westfield on the ASX showing far greater expected upside than for the Scentre Group’s Australian-New Zealand exposure. So much so that there have…
Does Buffett still have the magic touch? It seems as if Japan does not get a lot of respect from external investors.
In the second of a series on Australian biotech success stories, here are some more representatives of the fascinating medical device cohort on the ASX. Medical Developments International (MVP, $5.97) Market capitalisation: $391 million Three-year total return: 6.3% a year Analysts’ consensus target price: $8.61 (Thomson Reuters) Medical Developments International is the company behind the…
Semiconductors would have to be one of the most pervasive and critical pieces of technology in our daily lives – but they are usually not thought about very much. They certainly don’t seem to get the investment love like they should, or get talked about as much as, say, the FAANG stocks or electric vehicle…
Troy is a Partner and Adviser at Koda Capital. Troy is a FASEA-compliant financial adviser holding a Bachelor of Commerce and SMSF Specialist Advisor designation. He became a member of the Inside Network and an inaugural member of the Advisory Committee; seeking to learn from his peers and share his own wisdom from many years in the industry.
It’s hardly a fair comparison, is it? To put REA Group alongside Domain Holdings?
